Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).
- Revenue in USD (TTM)19.71m
- Net income in USD-220.43m
- Incorporated2013
- Employees226.00
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049
- Websitehttps://www.editasmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2Seventy Bio Inc | 91.50m | -254.15m | 462.25m | 425.00 | -- | 1.13 | -- | 5.05 | -7.58 | -7.58 | 2.57 | 8.19 | 0.1292 | -- | 4.82 | 215,284.70 | -35.89 | -- | -41.05 | -- | 81.88 | -- | -277.78 | -- | -- | -- | 0.00 | -- | 67.81 | -- | 13.02 | -- | -- | -- |
| Evolus Inc | 148.62m | -74.41m | 463.14m | 215.00 | -- | 24.97 | -- | 3.12 | -1.33 | -1.33 | 2.65 | 0.3288 | 0.6826 | 5.42 | 8.01 | 691,237.20 | -34.18 | -40.34 | -44.92 | -65.12 | 62.40 | -- | -50.07 | -123.95 | 1.76 | -6.64 | 0.7953 | -- | 49.10 | -- | -58.97 | -- | -- | -- |
| Janux Therapeutics Inc | 8.61m | -63.06m | 470.62m | 60.00 | -- | 1.46 | -- | 54.65 | -1.52 | -1.52 | 0.2077 | 7.71 | 0.0232 | -- | -- | 143,533.30 | -16.96 | -- | -17.65 | -- | -- | -- | -732.22 | -- | -- | -- | 0.00 | -- | 136.79 | -- | -93.01 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -44.73m | 471.68m | 33.00 | -- | 3.38 | -- | -- | -1.85 | -1.85 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -26.95 | -- | -27.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -135.41 | -- | -- | -- |
| Arbutus Biopharma Corp | 39.02m | -69.46m | 487.71m | 96.00 | -- | 3.45 | -- | 12.50 | -0.4589 | -0.4589 | 0.2585 | 0.8692 | 0.1951 | -- | 34.67 | 406,447.90 | -34.74 | -47.15 | -39.04 | -50.77 | -- | -- | -178.01 | -610.12 | -- | -- | 0.00 | -- | 255.11 | 29.53 | 21.42 | -- | -41.17 | -- |
| Editas Medicine Inc | 19.71m | -220.43m | 490.38m | 226.00 | -- | 1.36 | -- | 24.88 | -3.21 | -3.21 | 0.2871 | 5.24 | 0.0331 | -- | 7.28 | 87,216.81 | -36.99 | -29.45 | -40.64 | -32.55 | -- | -- | -1,118.32 | -409.97 | -- | -- | 0.00 | -- | -22.83 | 7.50 | -14.51 | -- | 14.87 | -- |
| Agenus Inc | 98.03m | -220.29m | 492.12m | 533.00 | -- | -- | -- | 5.02 | -0.778 | -0.778 | 0.348 | -0.2005 | 0.2229 | -- | 46.03 | 183,911.80 | -52.45 | -57.35 | -89.79 | -110.54 | 89.22 | -- | -235.30 | -107.06 | -- | -2.95 | -- | -- | -66.85 | 17.98 | -812.65 | -- | 76.24 | -- |
| Entrada Therapeutics Inc | 0.00 | -94.62m | 492.84m | 130.00 | -- | 2.20 | -- | -- | -3.02 | -3.02 | 0.00 | 6.77 | 0.00 | -- | -- | 0.00 | -33.92 | -- | -35.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -84.95 | -- | -- | -- |
| Cerus Corporation | 188.32m | -42.78m | 495.55m | 309.00 | -- | 7.33 | -- | 2.63 | -0.2424 | -0.2424 | 1.07 | 0.3807 | 0.8267 | 2.69 | 6.32 | 609,433.70 | -18.80 | -30.22 | -33.19 | -45.16 | 60.20 | 61.29 | -22.74 | -45.24 | 1.21 | -5.23 | 0.5045 | -- | 18.05 | 29.69 | 21.32 | -- | 41.47 | -- |
| iTeos Therapeutics Inc | 267.63m | 96.65m | 497.94m | 125.00 | 5.48 | 0.7507 | 5.11 | 1.86 | 2.55 | 2.55 | 7.09 | 18.57 | 0.3264 | -- | 36.85 | 2,141,040.00 | 11.79 | -- | 14.94 | -- | -- | -- | 36.11 | -- | -- | -- | 0.00 | -- | -22.38 | -- | -54.95 | -- | -- | -- |
| Coherus Biosciences Inc | 211.04m | -291.75m | 511.09m | 359.00 | -- | -- | -- | 2.42 | -3.76 | -3.76 | 2.72 | -1.74 | 0.3638 | 1.83 | 1.81 | 587,860.80 | -50.29 | -24.08 | -68.15 | -31.30 | 66.79 | -- | -138.24 | -41.34 | 2.47 | -7.91 | 1.41 | -- | -35.37 | 166.98 | -1.62 | -- | -14.92 | -- |
| Terns Pharmaceuticals Inc | 1.00m | -58.77m | 512.73m | 41.00 | -- | 2.19 | -- | 512.73 | -2.10 | -2.10 | 0.035 | 4.88 | 0.0054 | -- | -- | 24,390.24 | -31.56 | -- | -32.82 | -- | -- | -- | -5,877.10 | -- | -- | -- | 0.00 | -- | -- | -- | -70.88 | -- | -- | -- |
| BioXcel Therapeutics Inc | 375.00k | -165.76m | 513.47m | 183.00 | -- | 6.49 | -- | 1,369.25 | -5.92 | -5.92 | 0.0134 | 2.73 | 0.0017 | -- | -- | 2,049.18 | -74.45 | -63.32 | -83.77 | -69.75 | 94.67 | -- | -44,201.33 | -108,558.70 | 6.11 | -28.08 | 0.5479 | -- | -- | -- | -55.01 | -- | -- | -- |
| Zymeworks Inc | 412.48m | 124.34m | 516.81m | 291.00 | 4.59 | 1.06 | 3.93 | 1.25 | 1.76 | 1.76 | 6.32 | 7.64 | 0.7949 | -- | 16.83 | 1,417,464.00 | 23.96 | -23.31 | 28.57 | -28.03 | -- | -- | 30.14 | -80.27 | -- | -- | 0.0003 | -- | 1,446.03 | 51.45 | 158.69 | -- | 33.28 | -- |
| Alector Inc | 133.62m | -130.06m | 517.26m | 273.00 | -- | 2.41 | -- | 3.87 | -1.58 | -1.62 | 1.62 | 2.59 | 0.1668 | -- | 26.78 | 489,439.60 | -16.23 | -20.21 | -19.00 | -23.73 | -- | -- | -97.33 | -125.21 | -- | -- | 0.00 | -- | -35.48 | 104.51 | -258.00 | -- | 38.74 | -- |
| Fate Therapeutics Inc | 96.30m | -281.72m | 517.31m | 551.00 | -- | 1.06 | -- | 5.37 | -2.91 | -2.91 | 0.9946 | 4.97 | 0.1184 | -- | 4.08 | 174,773.10 | -34.63 | -33.76 | -39.36 | -38.16 | -- | -- | -292.55 | -418.09 | -- | -- | 0.00 | -- | 72.44 | 87.95 | -32.79 | -- | 83.17 | -- |
Data as of Mar 29 2023. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD
47.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 9.22m | 13.41% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 6.75m | 9.82% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 5.68m | 8.27% |
| Millennium Management LLCas of 31 Dec 2022 | 2.14m | 3.12% |
| Woodline Partners LPas of 31 Dec 2022 | 2.08m | 3.02% |
| Dimensional Fund Advisors LPas of 31 Dec 2022 | 1.65m | 2.40% |
| PFM Health Sciences LPas of 31 Dec 2022 | 1.47m | 2.13% |
| Geode Capital Management LLCas of 31 Dec 2022 | 1.38m | 2.01% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2022 | 1.10m | 1.60% |
| Two Sigma Advisers LPas of 31 Dec 2022 | 1.10m | 1.59% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
